Hoth Therapeutic Submits Ethics Approval Request for Atopic Dermatitis Trial

Hoth Therapeutics has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic BioLexa for Atopic Dermatitis. The ethics submission was made to the Bellberry Human Research Ethics Committee in Australia.

Hoth's proposed study will be a Randomized, Double-Blind, Vehicle Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis.

"Thanks to the hard work of our team and CRO partner Novotech, this ethics submission is yet another important step in the Company's clinical development program," Robb Knie, Chief Executive Officer of Hoth, said.

BioLexa is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach in treating atopic dermatitis.